Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 18/20 | 0.51 |
| ▸ | FPR1 | P21462 | 2/20 | 0.48 |
| ▸ | FPR2 | P25090 | 2/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4490369 | 0.89 | FPR1 (0.50) | F10FPR1FPR2F2 | |
| SCHEMBL4479417 | 0.84 | F10 (0.48) | F10FPR1FPR2 | |
| SCHEMBL4492314 | 0.80 | F10 (0.46) | F10FPR1FPR2F2 | |
| SCHEMBL4478092 | 0.80 | F10 (0.47) | F10FPR1FPR2 | |
| SCHEMBL5794813 | 0.77 | F10 (0.52) | F10FPR1FPR2 | |
| SCHEMBL8326106 | 0.76 | CASP3 (0.47) | F10FPR1FPR2 | |
| SCHEMBL4468906 | 0.74 | F10 (0.41) | F10FPR1FPR2 | |
| SCHEMBL4490372 | 0.73 | F10 (0.45) | F10FPR1FPR2 | |
| SCHEMBL4486077 | 0.73 | F10 (0.45) | F10F2 | |
| SCHEMBL4479418 | 0.73 | F10 (0.47) | F10FPR1FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157470-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-02 | — | — | US | claimed |
| US-7524863-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-28 | — | — | US | disclosed |
| US-7157470-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| EP-1501798-A4 | SULFONYLAMINOVALEROLAC TAMS AND DERIVATIVES THEREOF AS FACTOR Xa INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20060247243-A1 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | SMALLHEER JOANNE M | 2006-11-02 | — | — | US | disclosed |
| EP-1501798-A2 | SULFONYLAMINOVALEROLAC TAMS AND DERIVATIVES THEREOF AS FACTOR Xa INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2004041776-A2 | SULFONYLAMINOVALEROLAC TAMS AND DERIVATIVES THEREOF AS FACTOR Xa INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247243-A1 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | TFPI, SPINT2, F5 | F10 38/4885FPR1 2550/4885FPR2 3867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.